根据患者和医生的性别停止使用他类药物:一项观察性研究
Atsuyuki Watanabe1, Yoshihisa Miyamoto2, Hiroki A Ueyama3
1Department of Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Journal of cardiology
|February 25, 2026
概括
与男性医生相比,女性医生与早期停止使用他类药物的比率略低. 这一发现适用于男性和女性患者,他们开始使用他类药物治疗以进行初级预防.
科学领域:
- 心血管医学 心血管医学
- 医疗保健服务研究 医疗服务研究
- 临床药房 临床药房
背景情况:
- 使用美国国家医疗保险索赔数据的观察性研究.
- 专注于患者/医生性别和停用他类药物的关联.
- 检查了老年人初级预防的他类药物的使用.
研究的目的:
- 为了研究医生性别和早期停止使用他类药物的关系.
- 为了确定患者的性别是否会改变这种关联.
- 分析大,多样化的人口中的他类药物坚持模式.
主要方法:
- 对20%的Medicare受益者 (年龄在66-99岁) 开始服用他类药物的随机样本进行分析.
- 纳入标准:初级预防 (没有先前的心血管事件).
- 主要结局:提前停药 (1年内没有第二次处置),调整为共变量.
主要成果:
- 超过423,000名患者开始服用他类药物;10.2%的患者提前停止服用.
- 女性医生与早期停止治疗的调整后风险略低 (-0.4 pp; p<0.001).
- 这种效应在女性和男性患者中一致,无论糖尿病或他类药物的强度如何.
结论:
- 全国数据显示,女性医生处方他类药物,与早期停药率略低相关.
- 医生性别似乎是初级预防类他类药物的坚持的一个因素.
- 研究结果表明,患者与医生的沟通或护理模式可能存在基于性别的差异.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Atherosclerosis III: Management
516
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
516
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
273
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
273
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
316
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
316
Bioavailability Study Design: Healthy Subjects Versus Patients
192
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
192
Coronary Artery Disease V: Interprofessional Care
343
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
343

